Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.
Latest Ratings for HIMS
DateFirmActionFromTo Mar 2022Deutsche BankInitiates Coverage OnHold Dec 2021CitigroupMaintainsBuy Dec 2021JefferiesInitiates Coverage OnHold